Cdk4 and Nek2 Signal Binucleation and Centrosome Amplification in a Her2+ Breast Cancer Model

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Harrison Pitner, Mary Kathryn ^a   Saavedra, Harold I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE; PROTEIN KINASE NEK2; UNCLASSIFIED DRUG;

ARTICLE; BINUCLEATION; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CDK4 GENE; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CENTROSOME AMPLIFICATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; NEK2 GENE; ONCOGENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CENTROSOME; CYCLIN-DEPENDENT KINASE 4; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LENTIVIRUS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; S PHASE;

EID: 84878918789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065971     Document Type: Article

References (64)

1. Boveri T (1914) Zur Frage der Entstehung Maligner Tumoren (Jena: Fischer Verlag, 1914 (English translation by M. Boveri reprinted as The Origin of malignant tumors, The Williams and Wilkins Co., Baltimore), 1929.
2. Sluder G, Hinchcliffe EH, (1999) Control of centrosome reproduction: the right number at the right time. Biol Cell 91: 413-427.
3. Doxsey S, (2002) Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell 10: 439-440.
4. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, et al. (1998) Centrosome defects and genetic instability in malignant tumors. Cancer Research 58: 3974-3985.
5. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proceedings of the National Academy of Sciences of the United States of America 99: 1978-1983.
6. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, et al. (1999) Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18: 1935-1944.
7. Zyss D, Gergely F, (2009) Centrosome function in cancer: guilty or innocent? Trends Cell Biol 19: 334-346.
8. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL, (1998) Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A 95: 2950-2955.
9. Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, et al. (2007) Analysis of the cellular centrosome in fine-needle aspirations of the breast. Breast Cancer Res 9: R48.
10. Pihan GA, Wallace J, Zhou Y, Doxsey SJ, (2003) Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 63: 1398-1404.
11. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 99: 1978-1983.
12. Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, et al. (2008) Centrosome amplification can initiate tumorigenesis in flies. Cell 133: 1032-1042.
13. Castellanos E, Dominguez P, Gonzalez C, (2008) Centrosome dysfunction in Drosophila neural stem cells causes tumors that are not due to genome instability. Curr Biol 18: 1209-1214.
14. Weaver BA, Cleveland DW, (2007) Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67: 10103-10105.
15. Schliekelman M, Cowley DO, O'Quinn R, Oliver TG, Lu L, et al. (2009) Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res 69: 45-54.
16. Ganem NJ, Godinho SA, Pellman D, (2009) A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278-282.
17. Fukasawa K, (2007) Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 7: 911-924.
18. Krzywicka-Racka A, Sluder G, (2011) Repeated cleavage failure does not establish centrosome amplification in untransformed human cells. J Cell Biol 194: 199-207.
19. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043-1047.
20. Fukasawa K, (2005) Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19.
21. Gopinathan L, Ratnacaram CK, Kaldis P, (2011) Established and novel Cdk/cyclin complexes regulating the cell cycle and development. Results Probl Cell Differ 53: 365-389.
22. Satyanarayana A, Kaldis P, (2009) Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28: 2925-2939.
23. Hartwell LH, Weinert TA, (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629-634.
24. D'Assoro AB, Lingle WL, Salisbury JL, (2002) Centrosome amplification and the development of cancer. Oncogene 21: 6146-6153.
25. Harrison MK, Adon AM, Saavedra HI, (2011) The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div 6: 2.
26. Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, et al. (2010) Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol 30: 694-710.
27. Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, et al. (2005) Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280: 768-776.
28. Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, et al. (2010) The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene 29: 5103-5112.
29. Harari D, Yarden Y, (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19: 6102-6114.
30. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
31. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, et al. (2006) Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9: 23-32.
32. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, et al. (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127-140.
33. Lacey KR, Jackson PK, Stearns T, (1999) Cyclin-dependent kinase control of centrosome duplication. Proceedings of the National Academy of Sciences of the United States of America 96: 2817-2822.
34. Matsumoto Y, Hayashi K, Nishida E, (1999) Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Current Biology 9: 429-432.
35. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G, (1999) Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283: 851-854.
36. D'Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, et al. (2004) Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene 23: 4068-4075.
37. Hanashiro K, Kanai M, Geng Y, Sicinski P, Fukasawa K (2008) Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene.
38. Tarapore P, Horn HF, Tokuyama Y, Fukasawa K, (2001) Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene 20: 3173-3184.
39. Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, et al. (2006) Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 25: 2943-2949.
40. Ray D, Terao Y, Christov K, Kaldis P, Kiyokawa H, (2011) Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia 13: 439-444.
41. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, et al. (2005) Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 65: 10174-10178.
42. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, et al. (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672-683.
43. Yu Q, Geng Y, Sicinski P, (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.
44. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, et al. (2012) Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 104: 476-487.
45. Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, et al. (2003) Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 107: 346-352.
46. Montagna C, Andrechek ER, Padilla-Nash H, Muller WJ, Ried T, (2002) Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 21: 890-898.
47. Salisbury JL, D'Assoro AB, Lingle WL, (2004) Centrosome amplification and the origin of chromosomal instability in breast cancer. J Mammary Gland Biol Neoplasia 9: 275-283.
48. Gao Y, Niu Y, Wang X, Wei L, Zhang R, et al. (2011) Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer. Hum Pathol 42: 1693-1701.
49. Bouchet BP, Bertholon J, Falette N, Audoynaud C, Lamblot C, et al. (2007) Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype. Br J Cancer 97: 1218-1224.
50. Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, et al. (2003) Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3: 333-346.
51. Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, et al. (2010) The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene.
52. Anderhub SJ, Kramer A, Maier B (2012) Centrosome amplification in tumorigenesis. Cancer Lett.
53. Fry AM, Meraldi P, Nigg EA, (1998) A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. Embo J 17: 470-481.
54. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, et al. (2009) Division and apoptosis of E2f-deficient retinal progenitors. Nature 462: 925-929.
55. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, et al. (2009) E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462: 930-934.
56. Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, et al. (2004) The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 64: 7370-7376.
57. Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K, (2001) Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. Journal of Biological Chemistry 276: 21529-21537.
58. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ, (1999) MAPK mediates RAS-induced chromosome instability. J Biol Chem 274: 38083-38090.
59. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, et al. (2000) The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19: 3948-3954.
60. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF, (1996) Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747.
61. Fukasawa K (2008) p53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta.
62. Hayward DG, Fry AM, (2006) Nek2 kinase in chromosome instability and cancer. Cancer Lett 237: 155-166.
63. Prigent C, Glover DM, Giet R, (2005) Drosophila Nek2 protein kinase knockdown leads to centrosome maturation defects while overexpression causes centrosome fragmentation and cytokinesis failure. Exp Cell Res 303: 1-13.
64. Tsunoda N, Kokuryo T, Oda K, Senga T, Yokoyama Y, et al. (2009) Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 100: 111-116.